Liquid paraffin
Liquid paraffin is a mineral-oil lubricant laxative used for the short-term relief of constipation; it is also used as a lubricant in some ophthalmic and skin preparations.
Adult dose
Paediatric dose
Dose adjustments
Not stated — the SPC contains no renal-impairment statement.
Not stated — the SPC contains no hepatic-impairment statement.
Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via MHRA Products — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.
Contraindications
- Children under 3 years (§4.3)
- Patients with undiagnosed abdominal symptoms, as for other laxatives (§4.3)
Side effects
- Anal seepage of paraffin and consequent anal irritation after prolonged use (§4.8)
- Granulomatous reactions caused by absorption of liquid paraffin (§4.8)
- Lipoid pneumonia (by accidental inhalation) — caution is required in patients with swallowing difficulties (§4.8)
Interactions
- There may be interference with the absorption of fat soluble vitamins (§4.5)
Clinical monograph
How it works
Taken orally it lubricates and softens the faecal mass by coating the stool and bowel wall, easing passage.
Prescribing in practice
- Aspiration of liquid paraffin can cause lipoid pneumonia, so avoid use in those at risk of aspiration and do not take immediately before lying down.
- Prolonged use may impair absorption of fat-soluble vitamins and cause anal seepage with irritation, so it is intended only for short-term use.
- It is not recommended in young children because of the aspiration risk; reserve oral use for short-term relief in suitable patients.
Monitoring
Routine laboratory monitoring is not required for short-term use; review the response and avoid prolonged or repeated courses.
Counselling the patient
- Use this only for short-term relief and do not take it just before going to bed or lying down.
- See your clinician if constipation persists rather than continuing it long term.
Evidence & guidelines
Liquid paraffin is a recognised laxative whose use is limited by aspiration and absorption concerns, consistent with cautions in current prescribing references.
Reference: Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Lower Gastrointestinal Bleed · BSG 2019
- Variceal Upper GI Bleed · BSG 2015; Baveno VII (2022)
- Spontaneous Bacterial Peritonitis (SBP) · BSG / EASL 2018
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Hepatic Encephalopathy · EASL 2014; West Haven criteria
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021